Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacotherapy and Intensive Treatment of Drug Abuse - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00000217
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : April 16, 2015
Sponsor:
Collaborators:
National Institute on Drug Abuse (NIDA)
US Department of Veterans Affairs
Information provided by (Responsible Party):
University of Kansas Medical Center ( University of Kansas )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.

Condition or disease Intervention/treatment Phase
Cocaine-Related Disorders Substance-Related Disorders Drug: Carbamazepine Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Pharmacotherapy and Intensive Treatment of Drug Abuse
Study Start Date : September 1990
Actual Primary Completion Date : October 1996

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Drug use
  2. Effectiveness of medication
  3. Level of pharm
  4. Retention
  5. Depression, anxiety

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000217


Locations
Layout table for location information
United States, Missouri
University of Kansas
Kansas City, Missouri, United States, 64128
Sponsors and Collaborators
University of Kansas
National Institute on Drug Abuse (NIDA)
US Department of Veterans Affairs
Investigators
Layout table for investigator information
Principal Investigator: William Haning, M.D. University of Kansas
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:
J Addictive Dis. 13; 1994

Layout table for additonal information
Responsible Party: University of Kansas
ClinicalTrials.gov Identifier: NCT00000217    
Other Study ID Numbers: NIDA-06954-1
R18DA006954 ( U.S. NIH Grant/Contract )
R18-06954-1
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: April 16, 2015
Last Verified: April 2015
Keywords provided by University of Kansas Medical Center ( University of Kansas ):
drug abuse
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Substance-Related Disorders
Cocaine-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Carbamazepine
Anticonvulsants
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
 Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers